Ph D Degree in Physiology and Neuroscience at University of Medicine and Dentistry of New Jersey
M D degree in Medicine at Capital Institute of Medicine in Beijing China
Dr. Francine Fang joined 3E Bioventures as partner in May 2015. She focuses on investment in healthcare sector covering drug discovery, medical devices, in vitro diagnostics and medical services.
Prior to 3E Bioventures, Francine worked at Fidelity Growth Partners Asia (FGPA) as venture partner from 2014-2015. She led the investment transactions of Eyebright and Cytoville (Cytek).
Prior to FGPA, Francine gained 6 years of experience in Tuspark Venture. She led and was involved in various investment transactions including ACCB Bio, Shenogen pharma, Northland biotech, Hinacom, Larvia, Healthcare, Eyebright, Quantobio et.
From 1998 to 2007, Francine worked at Clontech and BD Biosciences as a group leader in R&D for near 10 years in US. She led the assay development for high content screening in BioImaging group at BD Biosciences in San Jose. Before BD acquisition she led the cell biology group at Clontech for the commercialization of multi-color fluorescent proteins and signal transduction product.
From 1996 to 1997, Francine worked as a postdoctor in Physiology at University of Medicine and Dentistry of New Jersey. She got Postdoctoral Fellowship from American Heart Association.
Francine has Ph.D. degree in Physiology and Neuroscience at University of Medicine and Dentistry of New Jersey and M.D. degree in Medicine at Capital Institute of Medicine in Beijing China.